Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Titan Pharmaceuticals Stock Quote

Titan Pharmaceuticals (NASDAQ: TTNP)

$7.26
(-0.0%)
-$0.00
Price as of April 15, 2024, 10:11 a.m. ET

Titan Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
TTNP -54.07% -99.29% -62.81% -100%
S&P +22.34% +74.52% +11.78% +732%

Titan Pharmaceuticals Company Info

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.